CA3148303A1 — Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
Assigned to Intra Cellular Therapies Inc · Expires 2015-06-11 · 11y expired
What this patent protects
The disclosure provides the use of substituted heterocycle fused gamma-carboline compounds of Formula I as pharmaceuticals for the treatment of bipolar disorders. The disclosure also provides foimulations of substituted heterocycle fused gamma-carboline compounds of Formula I …
USPTO Abstract
The disclosure provides the use of substituted heterocycle fused gamma-carboline compounds of Formula I as pharmaceuticals for the treatment of bipolar disorders. The disclosure also provides foimulations of substituted heterocycle fused gamma-carboline compounds of Formula I suitable for use in the treatment of bipolar disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.